



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

M327M

Food and Drug Administration  
Rockville MD 20857

JAN 3 2000

WARNING LETTER

VIA FEDERAL EXPRESS

Ref:OC:I1-1842

Mr. Rahn F. Smith  
Diagnostic Product Manager  
Leisegang Medical, Inc.  
6401 Congress Avenue  
Boca Raton, Florida 33487-2883

Dear Mr. Smith:

This letter is written to advise you of noncompliances with the Federal laser product performance standard encountered during review of the incomplete report on the SmoothLASE Alexandrite Laser, dated March 23, 1999, Accession Number 9910439. The information submitted was incomplete and a laser product reporting guide and further information were sent to you on April 9<sup>th</sup>, 1999, to be filled out and submitted as a report supplement but, to date, nothing further has been received. Please be advised that laser products manufactured after August 1, 1976, are subject to all the applicable requirements of the Federal performance standard for laser products specified in 21 CFR 1040.10 and 1040.11. It is unlawful for manufacturers: (1) to introduce such products into commerce if they fail to comply with the standard, or (2) to fail to submit reports as required by 21 CFR 1002.

Due to the inadequacy of information submitted, the following may be only a fraction of the noncompliances associated with the product.

1. 21 CFR 1040.11(a)(2). The SmoothLASE Operator's Manual lacks adequate calibration procedures and a calibration schedule, required to be supplied with each Class III and IV medical laser product. Although we would not object to your inclusion of statements to the effect that only authorized representatives of Leisegang Medical or Polaris Laser Systems may perform the procedure and that user recalibration would invalidate

the warranty, the requirement is clear that the instructions must be supplied to the purchaser.

You will recognize that this requirement is virtually identical in the IEC 825 standard.

2. 21 CFR 1010.2. The SmoothLASE laser lacks a certification label stating that the product complies with the Federal laser product performance standard.
3. 21 CFR 1010.3. The SmoothLASE laser lacks an identification label giving the manufacturing location and date of manufacture.
4. 21 CFR 1040.10(h)(1). The SmoothLASE Operator's Manual lacks certain radiation safety information specified in this section.
5. 21 CFR 1040.11(a)(3). The SmoothLASE laser lacks an aperture label.

Section 538(a) of the Federal Food, Drug, and Cosmetic Act, Chapter V, Subchapter C (formerly the Radiation Control for Health and Safety Act of 1968) prohibits any manufacturer from certifying or introducing into commerce laser products which do not comply with the standard. This section also prohibits any manufacturer from failure to establish and maintain required records or to submit required reports. Failure to respond to this letter may be considered to be in violation of section 538(a)(4) of the Act.

This letter is not intended to be an all-inclusive list of deficiencies. It is your responsibility to ensure adherence to each requirement of the Act and regulations. The specific violations noted in this letter may be symptomatic of serious underlying problems in your firm's manufacturing and quality assurance programs. You are responsible for investigating and determining the causes of the violations identified by the Food and Drug Administration (FDA). If the causes are determined to be systemic problems you must promptly initiate permanent corrective actions.

Federal agencies are advised of the issuance of all Warning Letters about devices so that they may take this information into account when considering the award of contracts. In cases where a foreign manufacturer fails to respond, penalties may be imposed upon importers.

Page 3 - Mr. Rahn F. Smith

You must respond in writing within 15 working days of receipt of this letter to one of the options listed below. In your response you must also provide the number of the referenced products which have been produced, the number of such products that have left the place of manufacture, and whether they were certified. In addition, if the product distribution was confined to specific geographical areas of the United States, please specify those areas.

1. Refutation - You may submit your views and evidence to establish that the alleged noncompliances do not exist.
2. Exemption Request - You may request an exemption from user and dealer/distributor notification and from obligation to correct the violative products. Your request must include the grounds upon which such exemption is requested (see 21 CFR 1003.30 and 1003.31).
3. Purchaser Notification and Corrective Action - If you neither refute the noncompliances nor request an exemption, then you must: (a) notify purchasers and dealers/distributors of the violative products as specified in 21 CFR 1003.10(b), and (b) submit a written corrective action plan (CAP) to fulfill your obligation under 21 CFR 1004.1 to repair, replace, or refund the cost of the violative products.
  - a. Notification Letter - Requirements for preparation of notification letters are prescribed in 21 CFR 1003.21 and 1003.22. A copy of the notification letter(s) sent to purchasers and dealers must also be sent to the FDA. It is recommended that you submit a draft of this letter to us for review.
  - b. Corrective Action Plan - Instructions for preparation of a CAP may be found in 21 CFR 1004.2, 1004.3, or 1004.4.

If you request additional time to prepare your refutation, notification, CAP, or evidence to support a requested exemption, you must provide the reasons for any delays and a reasonable target date for the full submission of your response. Be aware that if an acceptable CAP cannot be prepared promptly, you may be required to proceed with interim notification to affected persons as required by 21 CFR

Page 4 - Mr. Rahn F. Smith

1003.11(c) and 1003.21. Therefore, you are encouraged to immediately begin your preparation of accurate user location lists.

When you have completed any production changes necessary to assure compliance of future units and you have submitted the required reports and report supplements, you may resume introduction of these products into commerce.

Your response should be sent to: General Surgery Devices Branch, Division of Enforcement I (HFZ-323), Office of Compliance, Center for Devices and Radiological Health, 2098 Gaither Road, Rockville, Maryland 20850. Please send a copy of your response to: Compliance Branch (HFR-SE240), Food and Drug Administration, Florida District Office, 555 Winderley Place, Suite 200, Maitland, FL 32751.

If you have further questions on these requirements, please contact Ms. Cory Tylka of the General Surgery Devices Branch at phone: 301-594-4595, ext. 170, or FAX: 301-594-4636.

Sincerely yours,

*Lillian J. Gill*  
for/ Lillian J. Gill  
Director  
Office of Compliance  
Center for Devices and  
Radiological Health

1/3/00 *gunged*  
CRST